Farxiga

(Dapagliflozin)

ApprovedSmall molecule

Dapagliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, and it's also used to treat heart failure and chronic kidney disease to reduce the risk of hospitalization and death.[2] Farxiga is currently approved and in use across 92 indications[4].[1]

Farxiga is one of 1309 small molecule programs targeting Lupus Nephritis. It is currently in Approved.

Indications

516

Total Trials

Active Trials

1,308

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Lupus NephritisCompleted

Type 2 DiabetesCompleted

ObesityCompleted

NASH/MASHApproved

Type 1 DiabetesUnknown status

Left Ventricular HypertrophyActive, not recruiting

Myocardial FibrosisActive, not recruiting

Type 2 Diabetes MellitusUnknown status

Diabetes MellitusUnknown status

Heart FailureUnknown status

Lupus NephritisApproved

Completed

Type 2 DiabetesApproved

Completed

ObesityApproved

Completed

NASH/MASHApproved

Approved

Type 1 DiabetesApproved

Unknown status

Left Ventricular HypertrophyApproved

Active, not recruiting

Myocardial FibrosisApproved

Active, not recruiting

Type 2 Diabetes MellitusApproved

Unknown status

Diabetes MellitusApproved

Unknown status

Heart FailureApproved

Unknown status

Showing 10 of 90 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

4 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Spravato

WWim Janssens

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Diabetes

NCT02879409

Post-ApprovalActive, not recruiting

Diabetic Nephropathy

NCT06532682

Phase 3Not yet recruiting

Heart Failure

NCT06434025

Phase 3Recruiting

Chronic Kidney Disease

NCT05944016

Phase 1/2Recruiting

Dapagliflozin

NCT07239011

N/ARecruiting

Peritoneal Dialysis

NCT06398977

Clinical

Trials by Indication[1]

Dapagliflozin33 trials

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Completed·TThe University of Texas Health Science Center at San Antonio·N/A·NCT01439854·18 enrolled

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Completed·UUniversity at Buffalo·Phase 4·NCT02433678·52 enrolled

Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02383238·59 enrolled

Show 30 more trials

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT01068756·14 enrolled

Dapagliflozin DPPIV Inhibitor add-on Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00984867·833 enrolled

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01002807·15 enrolled

Effect of Dapagliflozin on Glycemic Variability

Completed·TThe Catholic University of Korea·Phase 4·NCT02459353·86 enrolled

Dapagliflozin in Depression

Recruiting·TTanta University·Phase 1/2·NCT07239011·60 enrolled

Dapagliflozin Efficacy and Action in PCOS

Completed·NNanfang Hospital, Southern Medical University·Phase 3·NCT04213677·165 enrolled

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00842556·18 enrolled

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT02981966·32 enrolled

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05429593·152 enrolled

Dapagliflozin on Volume Vascular Outcomes.

Completed·FFrank Ruschitzka·Phase 4·NCT04869124·80 enrolled

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00839683·24 enrolled

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00908271·7 enrolled

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT02984644·30 enrolled

Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

Completed·SSeoul National University Hospital·N/A·NCT02420392·30 enrolled

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00930865·42 enrolled

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Unknown status·MMedical University of Vienna·Phase 4·NCT05443932·32 enrolled

A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01072578·16 enrolled

Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04564742·4,017 enrolled

Effects of Single Oral Dose Dapagliflozin QT Study

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00688493·36 enrolled

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03316131·36 enrolled

Effect of Dapagliflozin on LV Remodeling Post AMI

Unknown status·IInstituto Mexicano del Seguro Social·Phase 4·NCT04783870·60 enrolled

Dapagliflozin (DAPA) Effects in HFpEF

Completed·MMayo Clinic·Phase 2·NCT04730947·38 enrolled

Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy

Completed·UUniversity of Ioannina·Phase 4·NCT02798757·50 enrolled

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01135446·35 enrolled

Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

Completed·UUppsala University·Phase 2·NCT02313220·50 enrolled

Effect of Dapagliflozin on IAH in T1DM

Completed·RRadboud University Medical Center·Phase 2·NCT03556033·15 enrolled

Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors

Completed·UUniversity of Padova··NCT04304430·11,206 enrolled

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Withdrawn·UUniversity Hospital Tuebingen·Phase 4·NCT03423355

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02582840·42 enrolled

Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?

Recruiting·OOslo University Hospital·Phase 4·NCT05788276·330 enrolled

Type 2 Diabetes26 trials

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT02719132

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02419612·444 enrolled

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00528879·915 enrolled

Show 23 more trials

Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients

Completed·MMajianhua·Phase 4·NCT03982238·74 enrolled

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT03338855·26 enrolled

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

Terminated·—·Phase 4·NCT05139914·4 enrolled

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Completed·UUniversity Medical Center Groningen·Phase 2·NCT05570305·42 enrolled

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Completed·UUniversity of Michigan·Phase 4·NCT02973477·45 enrolled

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Unknown status·WWonju Severance Christian Hospital·Phase 4·NCT05194592·122 enrolled

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Recruiting·TThe George Institute·Phase 3·NCT05345327·994 enrolled

Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.

Terminated·HHellenic Society for Medical Education·Phase 4·NCT02887677·85 enrolled

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

Completed·UUniversity of Liverpool·Phase 4·NCT02616666·632 enrolled

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00736879·497 enrolled

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01392677·311 enrolled

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00673231·1,240 enrolled

Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

Suspended· AstraZeneca logo

AstraZeneca·Phase 3·NCT01257412·375 enrolled

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Completed·TTulane University School of Medicine·Phase 4·NCT02796170·11 enrolled

The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes

Unknown status·SSun Yat-sen University·Phase 4·NCT06127433·210 enrolled

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01095653·1,179 enrolled

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01619059·315 enrolled

The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 3·NCT04634500·200 enrolled

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02284893·461 enrolled

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01095666·1,484 enrolled

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01646320·320 enrolled

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

Completed·UUppsala University·Phase 4·NCT02765204·15 enrolled

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Unknown status·YYooyoung Pharmaceutical Co., Ltd.·Phase 3·NCT05226897·256 enrolled

Heart Failure20 trials

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03036124·4,744 enrolled

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Completed·—·Phase 4·NCT04385589·100 enrolled

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Recruiting·—·Phase 4·NCT04707261·1,990 enrolled

Show 17 more trials

Effect of Dapagliflozin on VT in Patients With Heart Failure.

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT05550441·120 enrolled

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Unknown status·—·Phase 2·NCT04304560·60 enrolled

Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice

Completed· AstraZeneca logo

AstraZeneca··NCT05250011·252 enrolled

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Recruiting·TThe People's Hospital of Gaozhou·Phase 4·NCT06365541·40 enrolled

SGLT2-Inhibitors for Sleep Apnea in Heart Failure

Withdrawn·—·Phase 2·NCT04640493

Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

Completed·FFundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia·Phase 3·NCT04707352·162 enrolled

The Effect of Inflammation in Heart Failure

Withdrawn·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT05330013

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03877237·313 enrolled

Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

Unknown status·SScripps Health·Phase 4·NCT04570865·100 enrolled

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03877224·504 enrolled

Dapa Acute Heart Failure Study

Unknown status·—··NCT05759000·100 enrolled

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Completed·—·Phase 4·NCT04575675·78 enrolled

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

Completed·UUniversity of Dundee·Phase 4·NCT02397421·56 enrolled

Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction

Not yet recruiting·—·N/A·NCT06510270·70 enrolled

IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency

Not yet recruiting·HHospital de Clinicas de Porto Alegre·Phase 3·NCT06434025·99 enrolled

Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

Completed·FFatima Maqsood·N/A·NCT06915870·108 enrolled

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Completed·VVanderbilt University Medical Center·Phase 3·NCT04298229·240 enrolled

Type 2 Diabetes Mellitus14 trials

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Completed·MMedical University of Vienna·Phase 4·NCT03007329·34 enrolled

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT03152084·24 enrolled

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01165268·24 enrolled

Show 11 more trials

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03199053·256 enrolled

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT00663260·631 enrolled

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01031680·922 enrolled

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02725593·72 enrolled

Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01055652·28 enrolled

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04014192·40 enrolled

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00263276·389 enrolled

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT02426541·55 enrolled

Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01294436·728 enrolled

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT04120623·100 enrolled

Chronic Kidney Disease10 trials

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT04492722·613 enrolled

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

Recruiting·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2/3·NCT05713851·100 enrolled

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04595370·153 enrolled

Show 7 more trials

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 4·NCT06610526·731 enrolled

Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

Completed·KKaohsiung Medical University·Phase 3·NCT05196347·180 enrolled

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Recruiting·MMansoura University·Phase 2·NCT06897605·80 enrolled

Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients

Recruiting·UUniversity Hospital Goettingen·Phase 3·NCT05944016·102 enrolled

Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

Completed·—··NCT04882813·87,727 enrolled

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

Completed·MMansoura University·Phase 4·NCT05735197·100 enrolled

GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Completed·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 2/3·NCT05998837·34 enrolled

64 more indications

Type 1 Diabetes10 trials

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Completed·YYoungene Therapeutics Inc., Ltd.·Phase 2·NCT04956263·19 enrolled

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01498185·171 enrolled

Dapagliflozin in Type 1 Diabetes

Completed·MMedical University Innsbruck·Phase 4·NCT02211742·12 enrolled

Show 7 more trials

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Completed·UUniversity at Buffalo·Phase 3·NCT02518945·26 enrolled

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02268214·833 enrolled

Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes

Completed·KKinderkrankenhaus auf der Bult·Phase 1·NCT02987738·30 enrolled

Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)

Terminated·KKinderkrankenhaus auf der Bult·Phase 1·NCT04234867·2 enrolled

Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes

Completed·KKinderkrankenhaus auf der Bult·Phase 1·NCT02325206·36 enrolled

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

Completed·UUniversity at Buffalo·N/A·NCT02962492·70 enrolled

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

Completed·UUniversity at Buffalo·N/A·NCT02777073·43 enrolled

Peritoneal Dialysis3 trials

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Recruiting·SSichuan Academy of Medical Sciences·N/A·NCT06398977·70 enrolled

Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

Recruiting·OOman Ministry of Health·N/A·NCT07491042·38 enrolled

The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

Completed·—·N/A·NCT04923295·20 enrolled

Drug3 trials

Effect of Anti-diabetic Drugs on Glycemic Variability

Completed·CCentro de Diabetes Curitiba Ltda·Phase 4·NCT02925559·135 enrolled

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown status·—··NCT05347459·100 enrolled

A Phase IV Study in Drug-Naive Patients With T2DM in China

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT03344341·304 enrolled

Myocardial Infarction3 trials

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Completed·TThe TIMI Study Group·Phase 4·NCT04363697·2,401 enrolled

The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats

Completed·—·Phase 4·NCT07083232·50 enrolled

Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

Active, not recruiting·HHospital Clinic of Barcelona·Phase 3·NCT06619600·54 enrolled

Diabetes Mellitus3 trials

Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT05262257·120 enrolled

Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2

Unknown status·RResearch Clinical Centre of the Russian Railways, JSC·Phase 4·NCT02719756·100 enrolled

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

Not yet recruiting·EEMS·Phase 3·NCT05886088·597 enrolled

Diabetic Nephropathy2 trials

Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

Unknown status·TThe First Affiliated Hospital of Dalian Medical University·N/A·NCT05418465·100 enrolled

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

Active, not recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT06532682·54 enrolled

Overweight2 trials

Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.

Completed·SSun Jia·Phase 4·NCT06383832·36 enrolled

Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT03961659·87 enrolled

Metformin2 trials

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01055691·120 enrolled

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00643851·994 enrolled

Mitral regurgitation2 trials

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)

Unknown status·SSun Yat-sen University·Phase 4·NCT05848102·166 enrolled

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling

Unknown status·SSun Yat-sen University·Phase 4·NCT05606718·98 enrolled

Endothelial Function2 trials

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Unknown status·SSeoul National University Hospital·Phase 4·NCT02501616·22 enrolled

Effect of Dapagliflozin on Inflammation and Endothelial Function

Terminated·—·Phase 4·NCT02608905·17 enrolled

Breast Cancer2 trials

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated· Novartis logo

Novartis·Phase 2·NCT04899349·2 enrolled

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Unknown status·SSaint Luke's Health System·Phase 2·NCT05025735·25 enrolled

Insulin Sensitivity2 trials

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT02981069·90 enrolled

Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity

Unknown status·AAndrea Giaccari·Phase 3·NCT03313752·52 enrolled

Kidney Disease2 trials

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT06528405·264 enrolled

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Completed·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 4·NCT03919656·60 enrolled

Hypertension2 trials

Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension

Unknown status·UUniversity of Guadalajara·Phase 4·NCT03592667·20 enrolled

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Completed·UUniversity of Guadalajara·Phase 4·NCT03006471·30 enrolled

Diabetes2 trials

HbA1c Variability in Type II Diabetes

Active, not recruiting·WWeill Cornell Medical College in Qatar·N/A·NCT02879409·150 enrolled

Replication of the DECLARE Diabetes Trial in Healthcare Claims

Completed·—··NCT04215523·49,790 enrolled

Kidney Transplant2 trials

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

Completed·UUniversity Health Network, Toronto·Phase 3·NCT04965935·52 enrolled

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT06140537·80 enrolled

Cardiac2 trials

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

Unknown status·HHospital General Universitario Gregorio Marañon·Phase 4·NCT04739215·62 enrolled

Epicardial Cardiac Fat-CT (EPIC-CT)

Recruiting·IInstituto Mexicano del Seguro Social·Phase 3·NCT07297589·136 enrolled

Type 2 Diabetic Patients1 trial

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT02338921·78 enrolled

Left Ventricular Hypertrophy1 trial

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Completed·UUniversity of Dundee·Phase 4·NCT02956811·66 enrolled

Clinical Trial1 trial

A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Unknown status·KKyung Hee University Hospital at Gangdong·Phase 4·NCT04706637·120 enrolled

Albuminuria1 trial

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

Completed·UUniversity Health Network, Toronto·Phase 4·NCT02585804·10 enrolled

Pancreatic Cancer1 trial

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Completed·WWashington University School of Medicine·Phase 1·NCT04542291·15 enrolled

Renal Impairment1 trial

Renal Impairment in Type 2 Diabetic Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00554450·40 enrolled

Polycystic Ovary Syndrome1 trial

Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome

Recruiting·FFuture University in Egypt·Phase 3·NCT06576375·70 enrolled

Inflammation1 trial

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Completed·WWashington University School of Medicine·Phase 1·NCT06812429·6 enrolled

Metabolic Syndrome1 trial

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Completed·UUniversity of Guadalajara·Phase 2/3·NCT02113241·24 enrolled

Polycystic Ovarian Syndrome1 trial

Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Not yet recruiting·—·Phase 3·NCT06405178·500 enrolled

COVID-191 trial

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

Completed·—·Phase 2/3·NCT04393246·454 enrolled

Impaired glucose tolerance1 trial

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Recruiting·TThe University of Texas Health Science Center at San Antonio·N/A·NCT02969798·700 enrolled

Insulin Secretion1 trial

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Completed·UUniversity of Guadalajara·Phase 4·NCT02700334·24 enrolled

Function1 trial

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

Recruiting·KKing's College Hospital NHS Trust··NCT06572215·44 enrolled

Oral1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT03364985·123 enrolled

Ventricular Function1 trial

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

Completed·MMackay Memorial Hospital·Phase 4·NCT03871621·76 enrolled

Weight loss1 trial

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Terminated·CChristopher Bell·Phase 2·NCT02520518·9 enrolled

Cirrhosis1 trial

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06147518·240 enrolled

Local1 trial

Foxiga Korea Local Phase 4 Study

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT02564926·125 enrolled

IgA Nephropathy1 trial

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Active, not recruiting·TTravere Therapeutics, Inc.·Phase 3·NCT03762850·406 enrolled

Alcoholic Fatty Liver Disease1 trial

Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05849220·144 enrolled

Alzheimer's Disease1 trial

Dapagliflozin In Alzheimer's Disease

Completed·—·Phase 1/2·NCT03801642·46 enrolled

PreDiabetes1 trial

SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT04401904·20 enrolled

Prostate Cancer1 trial

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Not yet recruiting·YYung NA·Phase 2·NCT07310433·60 enrolled

Geographic Atrophy1 trial

SGLT2 Inhibitors in Geographic Atrophy

Recruiting·WWashington University School of Medicine·Phase 2·NCT07174687·70 enrolled

Atrial Fibrillation1 trial

Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

Unknown status·KKun Hua·Phase 4·NCT05816733·348 enrolled

Empagliflozin1 trial

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Unknown status·LLG Chem·Phase 1·NCT03565458·48 enrolled

Nephrotic Syndrome1 trial

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

Active, not recruiting·MMansoura University·Phase 2/3·NCT07214818·75 enrolled

Systemic Right Ventricle1 trial

Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)

Unknown status·—·Phase 4·NCT05717257·50 enrolled

Efficacy and Safety1 trial

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02229396·695 enrolled

Pathophysiology1 trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Active, not recruiting·RRegion Skane·Phase 2·NCT04451837·200 enrolled

Lupus Nephritis1 trial

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Completed·MMansoura University·Phase 4·NCT05748925·84 enrolled

Safety and Efficacy1 trial

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Completed·TThe University of Texas Health Science Center at San Antonio·N/A·NCT02613897·56 enrolled

End-Stage Renal Disease1 trial

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease

Withdrawn·TTan Tock Seng Hospital·Phase 2/3·NCT04764097

Fabry Disease1 trial

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Unknown status·—·Phase 2·NCT05710367·46 enrolled

Cardiac Surgery1 trial

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

Active, not recruiting·AAmsterdam UMC·Phase 4·NCT05590143·784 enrolled

Acute Myocardial Infarction1 trial

Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)

Completed·IInstituto Mexicano del Seguro Social·N/A·NCT04717986·188 enrolled

Fasting Conditions1 trial

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Completed· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT04880993·30 enrolled

Pilot Study1 trial

Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Active, not recruiting·TTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation·Phase 4·NCT05782972·50 enrolled

Dialysis Patients1 trial

Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT05343078·5 enrolled

Endothelial Dysfunction1 trial

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT02919345·98 enrolled

Hemodialysis1 trial

SGLT2 Inhibition in Hemodialysis

Completed·MMedical University of Vienna·Phase 2·NCT05179668·220 enrolled

Coronary Artery Disease1 trial

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Terminated·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT04330079·2 enrolled

Cardiovascular Events1 trial

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01730534·17,190 enrolled

Cardiotoxicity1 trial

Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT06341842·316 enrolled

Hyperglycemia1 trial

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

Active, not recruiting·LLauro Fabián Amador Medina·Phase 2·NCT06748105·38 enrolled

Unspecified5 trials

Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02060201·72 enrolled

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Completed·—·Phase 4·NCT03178591·43 enrolled

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT02592421·30 enrolled

Show 2 more trials

The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

Completed·UUniversity of California, San Francisco·Phase 2·NCT04818034·10 enrolled

Add-on to Thiazolidinedione (TZD) Failures

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00683878·972 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 8, 2014

FARXIGA

NDA NDA202293

Jan 8, 2014

FARXIGA

NDA NDA202293

Aug 8, 2014

FARXIGA

NDA NDA202293

Mar 11, 2015

FARXIGA

NDA NDA202293

Dec 4, 2015

FARXIGA

NDA NDA202293

Jan 6, 2016

FARXIGA

NDA NDA202293

Jan 12, 2016

FARXIGA

NDA NDA202293

Jun 14, 2016

FARXIGA

NDA NDA202293

Aug 17, 2016

FARXIGA

NDA NDA202293

Mar 1, 2017

FARXIGA

NDA NDA202293

Oct 20, 2017

FARXIGA

NDA NDA202293

Oct 26, 2018

FARXIGA

NDA NDA202293

Feb 22, 2019

FARXIGA

NDA NDA202293

Oct 18, 2019

FARXIGA

NDA NDA202293

Jan 24, 2020

FARXIGA

NDA NDA202293

Feb 3, 2020

FARXIGA

NDA NDA202293

May 5, 2020

FARXIGA

NDA NDA202293

Apr 30, 2021

FARXIGA

NDA NDA202293

Oct 13, 2022

FARXIGA

NDA NDA202293

Feb 17, 2023

FARXIGA

NDA NDA202293

May 8, 2023

FARXIGA

NDA NDA202293

Sep 12, 2023

FARXIGA

NDA NDA202293

Jun 12, 2024

FARXIGA

NDA NDA202293

Jun 3, 2026

FARXIGA

NDA NDA202293

Sources

References

[1]
ClinicalTrials.gov — 516 trial records for Dapagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Farxiga drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dapagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dapagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202293). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Farxiga. U.S. Food & Drug Administration.
[7]
PubMed — 2 publications indexed for Dapagliflozin. U.S. National Library of Medicine.
[8]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: SGLT2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Patent Landscape[6]

Patent Cliff

Mar 21, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8906851Aug 18, 2026

8329648Aug 18, 2026

8361972Mar 21, 2028

7851502Aug 19, 2028

8716251*PEDSep 21, 2028

17 more patents

8221786*PEDSep 21, 2028

7851502*PEDFeb 19, 2029

8721615Jan 18, 2030

8685934May 26, 2030

8721615*PEDJul 18, 2030

11826376Jul 18, 2039

12472194Jul 18, 2039

11826376*PEDJan 18, 2040

12472194*PEDJan 18, 2040

11903955Mar 9, 2040

10973836Mar 9, 2040

11903955*PEDSep 9, 2040

10973836*PEDSep 9, 2040

12213988Apr 1, 2041

12409186Apr 1, 2041

12409186*PEDOct 1, 2041

12213988*PEDOct 1, 2041

Key Publications[7]

Dapagliflozin in Chronic Kidney Disease: DAPA-CKD 2-Year Outcomes

Lancet Diabetes EndocrinolFeb 14, 2023DOI: 10.1016/S2213-8587(23)00027-X

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved EF: DELIVER

N Engl J MedSep 22, 2022DOI: 10.1056/NEJMoa2206286